This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Nivolumab for oesophageal or gastro-oesophageal junction cancer – adjuvant

< Back

Nivolumab for oesophageal or gastro-oesophageal junction cancer – adjuvant


Cancer and Palliative Care

July 2019

Nivolumab is a medicinal product that is being developed for the adjuvant treatment (after the primary treatment) of patients with resected oesophageal or gastro-oesophageal junction cancer. Oesophageal develops when abnormal cells in the gullet (oesophagus) grow in an uncontrolled way. The lower end of the oesophagus that joins the stomach is called the gastro oesophageal junction. Gastro oesophageal junction (GOJ) cancer develops at the point where the gullet joins the stomach, and is considered a separate type of cancer.
Nivolumab is a type of immunotherapy that is currently licensed in the UK for the treatment of several types of cancers such as melanoma, non-small cell lung cancer, and kidney cancer. Nivolumab works by improving the activity of a type of white blood cells called T-cells through blocking a protein called programmed death -1 (PD-1) on the surface of T-cells and thereby increasing the ability of the immune system to kill cancer cells. If licensed, nivolumab will offer an adjuvant treatment option for patients with resected oesophageal or GOJ cancer, who currently have few effective adjuvant therapies available.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts